

# Journal of Visualized Experiments

## Complementary Use of Microscopic Techniques and Fluorescence Reading in Studying Cryptococcus-Amoeba Interactions --Manuscript Draft--

<b>Article Type:</b>	Invited Methods Article - Author Produced Video
<b>Manuscript Number:</b>	JoVE58698R4
<b>Full Title:</b>	Complementary Use of Microscopic Techniques and Fluorescence Reading in Studying Cryptococcus-Amoeba Interactions
<b>Keywords:</b>	Amoeba, Cryptococcus, Fluorescence, Interactions, Model, Microscopy, Phagocytosis.
<b>Corresponding Author:</b>	Olihile M. Sebolai University of the Free State Bloemfontein, SOUTH AFRICA SOUTH AFRICA
<b>Corresponding Author's Institution:</b>	University of the Free State
<b>Corresponding Author E-Mail:</b>	SebolaiOM@ufs.ac.za
<b>Order of Authors:</b>	Uju L. Madu Olihile M. Sebolai
<b>Additional Information:</b>	
<b>Question</b>	<b>Response</b>
Please indicate whether this article will be Standard Access or Open Access.	Standard Access (US\$1200)

Tuesday, 23 April 2019

**Dr Jaydev Upponi, Ph.D.**

Science Editor: JoVE, Immunology and Infection

**Dear Dr Upponi,**

I have just uploaded a file of our revised manuscript i.e. 58698\_R4, entitled “Complementary Use of Microscopic Techniques and Fluorescence Reading in Studying *Cryptococcus*-Amoeba Interactions” by Madu and Sebolai, for your consideration. All authors approved the final version of the submitted manuscript.

Future correspondence should be addressed to Dr. Olihile M. Sebolai (+2751 401 2004; [sebolaiom@ufs.ac.za](mailto:sebolaiom@ufs.ac.za)).

I hope you will find all to be in order.

With sincere appreciation,



**Dr Olihile M. Sebolai (Ph.D.)**

Corresponding author

Senior Lecturer and Fulbright Fellow

**1 TITLE:**

2 Complementary Use of Microscopic Techniques and Fluorescence Reading in Studying  
3 *Cryptococcus*-Amoeba Interactions  
4

**5 AUTHORS AND AFFILIATION:**

6 Uju L. Madu<sup>1</sup>, Olihile M. Sebolai<sup>1</sup>  
7

8 <sup>1</sup>Department of Microbial, Biochemical and Food Biotechnology, University of the Free State,  
9 Park West, Bloemfontein, South Africa  
10

**11 Corresponding Author:**

12 Olihile M. Sebolai (sebolaiom@ufs.ac.za)  
13

**14 Email Address of Co-Author:**

15 Uju L. Madu (lynda.madu@yahoo.com)  
16

**17 KEYWORDS:**

18 amoeba, *Cryptococcus*, fluorescence, interactions, microscopy, model, phagocytosis  
19

**20 SUMMARY:**

21 This paper details a protocol for preparing a co-culture of cryptococcal cells and amoebae that  
22 is studied using still, fluorescent images and high-resolution transmission electron microscope  
23 images. Illustrated here is how quantitative data can complement such qualitative information.  
24

**25 ABSTRACT:**

26 To simulate *Cryptococcus* infection, amoeba, which is the natural predator of cryptococcal cells  
27 in the environment, can be used as a model for macrophages. This predatory organism, similar  
28 to macrophages, employs phagocytosis to kill internalized cells. With the aid of a confocal laser-  
29 scanning microscope, images depicting interactive moments between cryptococcal cells and  
30 amoeba are captured. The resolution power of the electron microscope also helps to reveal the  
31 ultrastructural detail of cryptococcal cells when trapped inside the amoeba food vacuole. Since  
32 phagocytosis is a continuous process, quantitative data is then integrated in the analysis to  
33 explain what happens at the timepoint when an image is captured. To be specific, relative  
34 fluorescence units are read in order to quantify the efficiency of amoeba in internalizing  
35 cryptococcal cells. For this purpose, cryptococcal cells are stained with a dye that makes them  
36 fluoresce once trapped inside the acidic environment of the food vacuole. When used together,  
37 information gathered through such techniques can provide critical information to help draw  
38 conclusions on the behavior and fate of cells when internalized by amoeba and, possibly, by  
39 other phagocytic cells.  
40

**41 INTRODUCTION:**

42 Microbes have evolved over time to occupy and thrive in different ecological niches such as the  
43 open physical boundaries of the soil and water, among others<sup>1</sup>. In these niches, microbes often  
44 engage in the direct competition for limited resources; importantly, for nutrients that they use

45 for supporting their growth or space, which they need to accommodate the expanding  
46 population<sup>2,3</sup>. In certain instances, some holozoic organisms like amoeba may even predate on  
47 cryptococcal cells as a way of extracting nutrients from their biomass<sup>4,5</sup>. In turn, this allows such  
48 organisms to establish territorial dominance via controlling the population numbers of its prey.  
49 Because of this predatory pressure, some prey may be selected to produce microbial factors,  
50 such as the cryptococcal capsule<sup>6</sup>, to reconcile the negative effects of the pressure. However, as  
51 an unintended consequence of this pressure, some microbes acquire factors that allow them to  
52 cross the species barrier and seek out new niches to colonize<sup>7</sup>, like the confined spaces of the  
53 human body that are rich in nutrients and have ideal conditions. The latter may explain how a  
54 terrestrial microbe like *Cryptococcus (C.) neoformans* can transform to become pathogenic.  
55

56 To this end, it is important to study the initial contact that cryptococcal cells may have with  
57 amoeba and how this may select them to become pathogenic. More specifically, this may give  
58 clues on how cryptococcal cells behave when acted upon by macrophages during infection. It is  
59 for this reason that amoeba was chosen as a model for macrophages here, as it is relatively  
60 cheap and easy to maintain a culture of amoeba in a laboratory<sup>8</sup>. Of interest was to also  
61 examine how cryptococcal secondary metabolites viz. 3-hydroxy fatty acids<sup>9,10</sup> influence the  
62 interaction between amoebae and cryptococcal cells.  
63

64 A simple way of perceiving the interaction between amoeba and its prey with the naked eye is  
65 to create a lawn using its prey on the surface of an agar plate and spot amoeba. The  
66 visualization of plaques or clear zones on the agar plate depicts areas where amoeba may have  
67 fed on its prey. However, at this macro level, only the outcome of the process is noted, and the  
68 process of phagocytosis is mechanized cannot be observed. Therefore, to appreciate the  
69 process on a cell-to-cell basis, there are several microscopic methods that can be used<sup>11,12</sup>. For  
70 example, an inverted microscope with an incubation chamber can be used to video record a  
71 time-lapse of events between a phagocytic cell and its target<sup>13</sup>. Unfortunately, due to the cost  
72 of a microscope with a time-lapse functionality, it is not always possible for laboratories to  
73 purchase such a microscope, especially in resource poor-settings.  
74

75 To circumvent the above limitation, this study presents a sequential exploratory design that  
76 evaluates the interaction of *C. neoformans* viz *C. neoformans* UOFS Y-1378 and *C. neoformans*  
77 LMPE 046 with *Acanthamoeba castellanii*. First, a qualitative method is used that precedes a  
78 quantitative method. Still images are captured using an inverted fluorescence microscope, as  
79 well as a transmission electron microscope to depict amoeba-*Cryptococcus* interactions. This  
80 was followed by quantifying fluorescence using a plate reader to estimate the efficiency of  
81 amoeba to internalize cryptococcal cells. When reconciling findings from these methods during  
82 the data-interpretation stage, this may equally reveal as much critical information as perusing a  
83 phagocytosis time-lapse video.  
84

## 85 **PROTOCOL:**

86

87 *Cryptococcus neoformans* and some *Acanthamoeba castellanii* strains are regarded as biosafety  
88 level-2 (BSL-2) pathogens; thus, researchers must take proper precautions when working with

89 these organisms. For example, laboratory personnel should have specific training and personal  
90 protective equipment (PPE) such as lab coats, gloves, and eye protection. A biological safety  
91 cabinet (level-2) should be used for procedures that can cause infection<sup>14</sup>.

92

### 93 **1. Cultivation and standardization of fungal cells (modified from Madu et al.<sup>15</sup>)**

94

95 1.1. Streak out the test fungal strains (i.e., *C. neoformans* UOFS Y-1378 and *C. neoformans* LMPE  
96 046) from stock cultures (no older than 9 months) on yeast-peptone-dextrose (YPD) agar plates.  
97 Information on YPD agar's ingredients can be found in **Table 1**.

98

99 NOTE: *C. neoformans* UOFS Y-1378 has been shown to produce 3-hydroxy fatty acids, while *C.*  
100 *neoformans* LMPE 046 does not produce 3-hydroxy fatty acids. Refer to **Supplemental File 1** for  
101 information on how the presence of these molecules is determined.

102

103 1.2. Incubate the agar plates for 48 h at 30 °C.

104

105 NOTE: A plate can be stored for up to 2 months at 4 °C before it can be discarded or used to  
106 make a stock culture<sup>16</sup>.

107

108 1.3. Scrape off a loopful of cryptococcal cells (*C. neoformans* UOFS Y-1378 or *C. neoformans*  
109 LMPE 046) from the 48 h-old plate and inoculate into a 250 mL conical flask containing 100 mL  
110 of the chemically-defined YNB broth (6.7 g/L) supplemented with 4% (w/v) glucose. Information  
111 on YNB broth's ingredients can be found in **Table 2**.

112

113 1.4. Incubate the flasks at 30 °C for 24 h while agitating at 160 rpm on a rotary shaker.

114

115 1.5. After a 24 h incubation period, count the fungal cells using a hemocytometer and adjust  
116 the cell number to  $1 \times 10^6$  cells/mL with PBS at pH 7.4.

117

118 NOTE: The prepared *C. neoformans* UOFS Y-1378 inoculum was used in steps 3.1 and 3.2, while  
119 *C. neoformans* LMPE 046 inoculum was only used in step 3.2.

120

### 121 **2. Cultivation and standardization of amoeba cells (modified from Madu et al.<sup>15</sup>)**

122

123 2.1. Thaw a stock culture of *Acanthamoeba castellanii* and bring it to room temperature (RT).

124

125 NOTE: Amoeba was prepared based on the modified protocols of Axelsson-Olsson et al.<sup>8</sup> and  
126 Schuster<sup>17</sup>.

127

128 2.2. Pipette 1 mL of the thawed culture and inoculate it into a 50 mL centrifuge tube containing  
129 15 mL of ATCC medium 712. Information on ATCC medium 712's ingredients can be found in  
130 **Table 3**.

131

132 2.3. Manually shake it gently and immediately centrifuge for 5 min at 400 x g and 30 °C.

- 133  
134 2.4. Aspirate the supernatant.  
135  
136 2.5. Resuspend the cells in 15 mL of ATCC medium 712 and incubate the tube at 30 °C for 14  
137 days.  
138  
139 NOTE: Periodically check the cells, using a simple light microscope, to determine if they are in a  
140 trophozoite state. Once they are in a trophozoite state, start a fresh culture.  
141  
142 2.6. Pipette 1 mL from a culture that shows cells in a trophozoite state and use it to inoculate a  
143 sterile 50 mL centrifuge tube containing 15 mL of fresh, sterile ATCC medium 712.  
144  
145 2.7. Incubate the tube at 30 °C for 1 week while agitating at 160 rpm on a rotary shaker.  
146  
147 2.8. After a week, count the amoeba cells using a hemocytometer and adjust the cell number to  
148  $1 \times 10^7$  cells/mL with fresh, sterile ATCC medium 712.  
149  
150 2.9. Perform a viability assay using a trypan blue stain as detailed by Strober<sup>18</sup>. Proceed further  
151 with the cultures that show at least 80% viability.  
152

### 153 **3. Fluorescence staining of cells to study phagocytosis (modified from Madu et al.<sup>15</sup>)**

#### 154 **3.1. Gathering qualitative data through use of fluorescence microscope**

155 NOTE: Perform this assay with *Acanthamoeba castellanii* and *C. neoformans* UOFS Y-1378.  
156

157 3.1.1. Dispense a 200- $\mu$ L suspension of standardized amoebae ( $1 \times 10^7$  cells/mL in ATCC  
158 medium 712) into chamber wells of an adherent slide and incubate for 2 h at 30 °C for cells to  
159 adhere to the surface.  
160  
161

162 3.1.2. While amoeba cells are settling down to adhere, stain the standardized *C. neoformans*  
163 UOFS Y-1378 cells that were adjusted to  $1 \times 10^6$  cells/mL (in 999  $\mu$ L of PBS) with 1  $\mu$ L of  
164 fluorescein isothiocyanate in a 1.5 mL plastic tube.  
165  
166

167 NOTE: Prepare the stain by dissolving 1 mg of fluorescein isothiocyanate in 1 mL of acetone.  
168

169 3.1.3. Gently agitate the *C. neoformans* UOFS Y-1378 cells on an orbital shaker set at 50 rpm for  
170 2 h at RT and in the dark.  
171

172 3.1.4. After 2 h, centrifuge at  $960 \times g$  for 5 min at 30 °C to pellet the cells.  
173

174 3.1.5 Aspirate the supernatant to remove the PBS with the stain.  
175

176 3.1.6. Add 1 mL of PBS to the tube for washing the cell pellet. Wash the cells by gently  
177 pipetting.  
178

179 3.1.8. Centrifuge the cells at 960 x *g* for 5 min at 30 °C. Discard the supernatant. Repeat the  
180 washing step one more time.  
181

182 3.1.9. Resuspend the washed cells in 1 mL of PBS.  
183

184 3.1.10. Dispense a 200 µL suspension of the stained *C. neoformans* UOFS Y-1378 cells to  
185 chamber wells containing the unstained amoeba cells.  
186

187 3.1.11. Incubate the prepared co-culture at 30 °C for an additional 2 h period.  
188

189 NOTE: The co-culture can be incubated for different time points to suit the purpose of the  
190 experiment.  
191

192 3.1.12. At the end of the co-incubation period, aspirate the contents of the wells.  
193

194 3.1.13. Add 300 µL of PBS to the wells to wash the chamber wells and to remove any unbound  
195 co-cultured cells. Do this by gentle pipetting. Aspirate the contents of the wells. Repeat the  
196 washing step one more time.  
197

198 3.1.14. Prepare the 3% glutaraldehyde solution by adding 3 mL of glutaraldehyde to 97 mL of  
199 distilled water.  
200

201 3.1.15. Fix the co-cultured cells by adding 250 µL of 3% solution to the chamber wells and  
202 incubating for 1 h.  
203

204 3.1.17. Aspirate the fixative and wash the chamber wells as detailed from step 3.1.13.  
205

206 3.1.18. Dismantle the chamber wells using a tool that was provided with the chamber slides.  
207

208 3.1.19. Add a drop of the antifade compound, 1,4-diazabicyclo-[2.2.2]-octane to the slide to  
209 prevent auto-bleaching. Cover with a coverslip and seal the sides with a nail polish to prevent  
210 evaporation.  
211

212 3.1.20. View the co-cultured cells using the 100x objective lens (with oil) of a confocal laser-  
213 scanning microscope.  
214

215 NOTE: It is important to take pictures in bright-field and fluorescence to view interaction  
216 between amoeba and cryptococcal cells. Wherever possible, the fluorescence can be super-  
217 imposed onto the bright-field images. Amoeba cells are typically larger in size (i.e., 45–60 µm),  
218 and the trophozoite cells have an irregular shape. Cryptococcal cells are 5–10 µm in diameter  
219 and have a globose to ovoid shape. When exposed to a laser, it is possible that unstained

220 amoeba cells may emit auto-fluorescence. Refer to Beisker and Dolbeare<sup>19</sup> and Clancy and  
221 Cauller<sup>20</sup> for methods to reduce autofluorescence.

222

### 223 **3.2. Acquiring quantitative data through use of fluorescence plate reader**

224

225 NOTE: Perform this assay with *Acanthamoeba castellanii* and *C. neoformans* UOFS Y-1378 or *C.*  
226 *neoformans* LMPE 046.

227

228 3.2.1. Dispense a 100  $\mu$ L suspension of standardized amoebae (adjusted to  $1 \times 10^7$  cells/mL in  
229 ATCC medium 712) into a black, adherent 96 well microtiter plate.

230

231 3.2.2. Incubate the plate for 2 h at 30 °C to allow amoeba cells to adhere to the surface.

232

233 3.2.3. While amoeba cells are settling down to adhere, stain the standardized *C. neoformans*  
234 UOFS Y-1378 cells that were adjusted to  $1 \times 10^6$  cells/mL (in 999  $\mu$ L of PBS) with 1  $\mu$ L of pHrodo  
235 Green Zymosan A BioParticles in a 1.5 mL microcentrifuge tube. Stain *C. neoformans* LMPE 046  
236 cells as well in a separate tube.

237

238 NOTE: The dye, unlike FITC, selectively stains cells that are trapped inside the acidic  
239 environment of a phagocytic cell<sup>21,22</sup>. For this technique, it is important to maintain the  
240 cryptococcal cells in a medium with a neutral pH (PBS) and amoeba in a medium with a neutral  
241 pH (ATCC medium 712). A medium with an acidic environment will result in a false positive  
242 reading of the relative fluorescence units, implying that a greater number of cryptococcal have  
243 been internalized.

244

245 3.2.4. Gently agitate cryptococcal cells on an orbital shaker set at 50 rpm for 2 h at RT and in  
246 the dark.

247

248 3.2.5. After 2 h, centrifuge the microcentrifuge tube at 960 x *g* for 5 min at 30 °C to pellet the  
249 cells. Aspirate the supernatant to remove PBS with the stain.

250

251 3.2.7. Add 1 mL of PBS to the tube to wash the pelleted cells. Wash the cells by gentle pipetting.

252

253 3.2.9. Centrifuge the cells at 960 x *g* for 5 min at 30 °C. Discard the supernatant. Repeat the  
254 washing step one more time.

255

256 3.2.10. Resuspend the pellet of washed cells in 1 mL of PBS.

257

258 3.2.11. Dispense a 100  $\mu$ L suspension of stained cryptococcal cells to wells containing unstained  
259 amoeba cells.

260

261 3.2.12. Incubate the prepared co-culture at 30 °C for an additional 2 h period.

262



263 NOTE: The co-culture can be incubated for different timepoints to suit the purpose of the  
264 experiment.

265  
266 3.2.13. At the end of the co-incubation period, measure the fluorescence on a microplate  
267 reader. Convert logarithmic signals to relative fluorescence units.

268  
269 NOTE: The dye's excitation is at 492 nm and emission is at 538 nm. Consult Beisker and  
270 Dolbear<sup>19</sup> and Clancy and Cauller<sup>20</sup> for methods to reduce autofluorescence.

271  
272 **4. Use of transmission electron microscopy to study phagocytosis (modified from van Wyk  
273 and Wingfield<sup>23</sup>)**

274  
275 4.1. Add a 5 mL suspension of amoebae (adjusted to  $1 \times 10^7$  cells/mL in ATCC medium 712) to a  
276 15 mL centrifuge tube and allow them to settle for 30 min at 30 °C.

277  
278 4.2 Add a 5 mL suspension of *C. neoformans* UOFS Y-1378 cells (adjusted to  $1 \times 10^6$  cells/mL in  
279 PBS) to the same centrifuge tube that contains 5 mL of standardized amoeba cells.

280  
281 4.3. Allow the tube stand for 2 h at 30 °C.

282  
283 4.4. Centrifuge the tube at  $640 \times g$  for 3 min at 30 °C to pellet the co-cultured cells. Aspirate the  
284 supernatant. Do not wash the co-cultured cells.

285  
286 4.6. Fix the co-cultured cells by resuspending the pellet in 3 mL of 1.0 M (pH = 7.0) sodium  
287 phosphate-buffered 3% glutaraldehyde for 3 h.

288  
289 4.8. Centrifuge the tube at  $1,120 \times g$  for 5 min at 30 °C to pellet the co-cultured cells. Aspirate  
290 the supernatant.

291  
292 4.10. Add 5 mL of sodium phosphate buffer to the centrifuge tube to wash the pelleted cells.  
293 Wash by gently pipetting the contents of the tube for 20 s.

294  
295 4.12. Centrifuge the tube at  $1,120 \times g$  for 5 min at 30 °C to pellet the co-cultured cells.

296  
297 4.13. Repeat steps 4.8–4.10. Aspirate the supernatant.

298  
299 4.15. Fix the co-cultured cells again by resuspending the pellet in 3 mL of 1.0 M (pH = 7.0)  
300 sodium phosphate-buffered 1% osmium tetroxide for 1.5 h.

301  
302 4.16. Remove the fixative (osmium tetroxide) by washing the co-cultured cells in a similar  
303 manner to removing 3% glutaraldehyde.

304  
305 4.17. Dehydrate the TEM material (also known as the co-cultured cells) in a graded acetone  
306 series of 30%, 50%, 70%, 95% and two changes of 100% for 15 min each, respectively. To do so,

307 add 3 mL of the acetone solution to the pelleted cells and let it stand for 15 min. Then,  
308 centrifuge at 200 x *g* for 10 min at RT Discard the supernatant and add the higher percentage of  
309 the acetone solution.

310

311 4.18. Prepare the epoxy of normal consistency according to the protocol by Spur<sup>24</sup>.

312

313 NOTE: The epoxy resin is used for sectioning.

314

315 4.19. Embed the TEM material into the freshly prepared epoxy resin. To do so, follow the steps  
316 below.

317

318 4.19.1. Add 3 mL of the freshly prepared epoxy to a tube that contains the TEM material  
319 resuspended in 3 mL of 100% solution of acetone. Allow the tube to stand for 1 h.

320

321 4.19.3. Centrifuge the tube at 200 x *g* for 10 min at 30 °C. Aspirate the epoxy-acetone solution.

322

323 4.19.5. Add 6 mL of the freshly prepared epoxy to the pellet in the tube. Allow the tube to stand  
324 for 1 h.

325

326 4.19.7. Centrifuge at 200 x *g* for 10 min at 30 °C. Aspirate all the epoxy-acetone solution.

327

328 4.19.9. Add 3 mL of the freshly prepared epoxy to the tube. Allow the tube to stand for 8 h.

329

330 4.19.11. Centrifuge at 200 x *g* for 10 min at 30 °C. Aspirate all the epoxy solution

331

332 4.19.13. Add 3 mL of the freshly prepared epoxy to the tube. Keep the TEM material in the  
333 epoxy solution overnight in a vacuum desiccator.

334

335 CAUTION: Epoxy resin is a radioactive material. Use PPE to handle the epoxy resin. The epoxy  
336 resin should also be handled in a fume hood. Researchers should follow safety regulations for  
337 discarding such material as specified by each country<sup>25</sup>.

338

339 4.20. Polymerize the TEM material for 8 h at 70 °C.

340

341 4.21. On the ultramicrotome, trim small sections of approximately 0.1 mm x 0.1 mm and 60 nm  
342 thickness from the epoxy-embedded material with a mounted glass knife. Assemble sections on  
343 a grid and place the grids in a TEM sample holder box before staining.

344

345 4.22. Stain the sections with a drop of 6% uranyl acetate for 10 min in the dark. Ensure the  
346 sections are completely covered.

347

348 NOTE: Reconstitute the stain (6 g) in 100 mL of distilled water.

349

350 CAUTION: Uranyl acetate is a radioactive material. Use PPE to handle uranyl acetate. Uranyl  
351 acetate should also be handled in a fume hood. Researchers should follow safety regulations  
352 for discarding such material as specified by each country<sup>25</sup>.

353

354 4.23. Rinse sections by dipping them five times into a beaker that contains 100 mL of distilled  
355 water.

356

357 NOTE: The distilled water should be disposed accordingly as it contains traces of uranyl acetate.

358

359 4.24. Stain the section with a drop of lead citrate for 10 min in the dark. Ensure the sections are  
360 completely covered.

361

362 NOTE: Lead citrate should be prepared according to the protocol by Reynold<sup>26</sup>.

363

364 4.25. Rinse sections by dipping them five times into a beaker that contains 100 mL of distilled  
365 water.

366

367 4.26. Individually assemble the grids with stained sections on a TEM sample holder box.

368

369 4.27. View sections with a transmission electron microscope.

370

#### 371 **REPRESENTATIVE RESULTS:**

372

373 Microbes are microscopic organisms that cannot be perceived with the naked eye. However,  
374 their impact may result in observable clinically evident illnesses, such as skin infections. When  
375 studying certain aspects of microbes, ranging from their morphology, byproducts, and  
376 interactions, being able to provide pictorial and video evidence is of the utmost importance.

377

378 We first sought to visualize the interaction between cryptococcal cells and amoeba. For this  
379 purpose, bright-field images that showed 2 h co-incubated cells were studied first. One image  
380 revealed a cryptococcal cell that was in the close proximity to amoeba. One of the amoeba cells  
381 was seen with extended pseudopodia to capture a cryptococcal cell (**Figure 1A**). Next, a  
382 corresponding image in fluorescence was captured for referencing (**Figure 1B**). The green  
383 fluorescence on the surface of the stained cells aided in confirming the presence of  
384 cryptococcal cells. The unstained amoeba also auto-fluoresced. This, in addition to the apparent  
385 difference size and morphology, assisted in further distinguishing the two cell types.

386

387 Autofluorescence is a quality often observed when biological structures naturally emit light that  
388 they have absorbed (e.g., following exposure to a laser during confocal laser scanning  
389 microscopy)<sup>27</sup>. In **Figure 1C**, cryptococcal cells were noted (at the same timepoint of 2 h) that  
390 were already internalized by amoeba. The corresponding image in fluorescence was also  
391 captured for referencing (**Figure 1D**). Based on the evidence at hand, it is tempting to conclude  
392 that the amoeba killed the two trapped cells. However, phagocytosis is a dynamic process  
393 wherein the host, predator and pathogen, and prey employ different strategies to destroy or

394 evade each other<sup>28</sup>. The act of cryptococcal cells evading phagocytic cells is elegantly  
395 demonstrated by vomocytosis<sup>29,30</sup>, which is a non-lytic expulsion of trapped cells from  
396 macrophages. This daring move has been captured in time-lapse videos<sup>29,30</sup>. Unfortunately, this  
397 highlights the limitation of studying still images of fixed cells, as in our study, to elucidate a  
398 dynamic process like phagocytosis. To the point, a researcher may miss the interval when a cell  
399 escapes from its capturer.

400  
401 To compensate for the above, the reading of relative fluorescence units was considered. In the  
402 current study, readings were taken after a 2 h co-incubation period and helped to compare the  
403 response of the two test cryptococcal strains [i.e., one that produces 3-hydroxy fatty acids (*C.*  
404 *neoformans* UOFS Y-1378) and the other that does not (*C. neoformans* LMPE 046)]. It was  
405 hypothesized that 3-hydroxy fatty acids may act as a virulence determinant that impair the  
406 uptake of cryptococcal cells, including phagocytosis by amoeba. For more information on the  
407 influence of 3-hydroxy fatty acids on amoeba, it is advised to refer to Madu et al.<sup>15,31</sup>. **Figure 2**  
408 shows the amount of cryptococcal cells that were internalized based on the reading of  
409 fluorescence units. When comparing the two cryptococcal isolates, it was clear that cells that  
410 produce the 3-hydroxy fatty acids were internalized less frequently compared to cells that do  
411 not produce 3-hydroxy fatty acids.

412  
413 To enhance the qualitative data, transmission electron microscopy was included in the analysis  
414 (**Figure 3A**). Here, it was noted that the strain that produces 3-hydroxy fatty acids (*C.*  
415 *neoformans* UOFS Y-1378) had spiky protuberances on the capsule (**Figure 3B**), which may be  
416 used by the cell to release 3-hydroxy fatty acids to the outside environment.

417  
418 It is important to note that the data (in **Figure 1**, **Figure 3**) convey the fate of cryptococcal cells  
419 as being internalized and not killed/phagocytized. To determine if the cells survived the  
420 phagocytic event, it is recommended to include an additional assay in which the researcher  
421 lyses the amoeba cells and prepares a spread plate agar to enumerate the cryptococcal colony  
422 forming units (CFU). By counting CFUs, Madu et al.<sup>15</sup> reported that cryptococcal cells producing  
423 3-hydroxy fatty acids were also resistant to the phagocytic action of amoeba following  
424 internalization. Thus, these cells yielded a significantly higher survival rate when compared to  
425 cells that do not produce 3-hydroxy fatty acids.

426  
427 **Figure 4** shows the importance of TEM sample preparation and examination. In this instance, *C.*  
428 *neoformans* UOFS Y-1378 sections were purposefully overexposed to electron bombardment.  
429 At the end, the captured image cannot be used, as it compromises the quality of information  
430 that can be deduced. Taken together, the obtained information shows that by combining these  
431 different techniques, a researcher is able to deduce sufficient information to determine the fate  
432 of cryptococcal cells when co-cultured with amoeba.

433

434 **FIGURE AND TABLE LEGENDS:**

435

436 **Table 1: Ingredients for making YPD agar.** Add the required amount all the ingredients in 1 L of  
437 water. Heat while stirring to dissolve the ingredients completely. Once done autoclave prior to  
438 the use.

439

440 **Table 2: Ingredients for making YNB broth.** Add the required amount all the ingredients in 1 L  
441 of water. Heat while stirring to dissolve the ingredients completely. Once done autoclave prior  
442 to the use.

443

444 **Table 3: Ingredients for making ATCC medium 712.** Prepare the basal medium in 900 mL of  
445 water. Prepare the supplements separately and add to the basal medium. Once done adjust the  
446 pH to 7.4 with 1 N HCl or 1 N NaOH and autoclave. Filter sterilize 50 mL solution of 2 M glucose  
447 (18 g/50 mL) and add it aseptically to the complete medium prior to use.

448

449 **Figure 1: Bright-field and corresponding fluorescent micrographs showing amoeba-**  
450 ***Cryptococcus* interactive moments. (A)** An amoeba cell in close proximity to a *C. neoformans*  
451 UOFS Y-1378 cell can be seen. The corresponding fluorescent image is shown in **(B)**. **(C)**  
452 Depiction of two *C. neoformans* UOFS Y-1378 cells that are trapped inside the amoeba food  
453 vacuole. The corresponding fluorescent image is shown in **(D)**. This figure has been modified  
454 from Madu et al.<sup>15</sup>. A = amoeba; C = *C. neoformans*.

455

456 **Figure 2: The results of the internalization assay of cryptococcal cells co-cultured with**  
457 **amoeba.** The reading of relative fluorescence units allows for the interpretation and  
458 comparison of the efficiency of amoebae to internalize *C. neoformans* UOFS Y-1378 and *C.*  
459 *neoformans* LMPE 046. The error bars represent the calculated standard errors based on three  
460 biological replicates. This figure has been modified from Madu et al.<sup>15</sup>.

461

462 **Figure 3: Transmission electron micrographs showing amoeba-*Cryptococcus* interactions.** TEM  
463 micrographs **(A, B)** confirm the observations in **Figure 1C,D**. **(A)** Shown is a *C. neoformans* UOFS  
464 Y-1378 cell trapped inside the amoeba food vacuole, while **(B)** is a close-up view of **Figure 3A**.  
465 This figure has been modified from Madu et al.<sup>15</sup>. A = amoeba cell; C = *C. neoformans* cell. The  
466 red arrow points at a capsular protuberance.

467

468 **Figure 4: A transmission electron micrograph showing *C. neoformans* UOFS Y-1378 cells.** The  
469 cells are damaged and thus cannot provide meaningful data. Red arrows indicate points where  
470 the section is torn.

471

## 472 **DISCUSSION:**

473

474 In the paper, different techniques were successfully employed to reveal the possible outcome  
475 that may arise when amoeba interact with cryptococcal cells. Also, we were interested to show  
476 the effects of 3-hydroxy fatty acids on the outcome of *Cryptococcus*-amoeba interactions.

477

478 The first technique used was confocal microscopy, which rendered still images. The major  
479 drawback of this technique here was that it only gave us information that is limited to a

480 particular timepoint. Any conclusion that can be drawn based on the results lends itself to  
481 inductive reasoning, wherein one can arrive at a conclusion based on a set of observations<sup>32</sup>.  
482 However, just because one observes several situations in which a pattern exists does not mean  
483 that that pattern is true for all situations. Thus, in the study, it is shown and possibly cautioned  
484 how such limited information may lead to unfounded conclusions. To the point, in the absence  
485 of contradictory or supportive, complementary evidence, it may be concluded that  
486 internalization may have led to the phagocytosis of cells.

487  
488 The pace of development in imaging brings new opportunities to make scientific discoveries, as  
489 was the case with the uncovering of vomocytosis<sup>29,30</sup>. To illustrate this point without use of a  
490 microscope that can record time-lapse videos, this discovery would have not been possible.  
491 Therefore, a lack of access to such high-end instrumentation will always be an obstacle in  
492 resource poor-settings that are not at the forefront of uncovering such processes. One way to  
493 overcome this is to seek out new collaborations or discover innovative ways to address  
494 research questions. One welcome development has been the introduction and application of  
495 specialized stains such as the phagocytic stain used here<sup>21,22</sup>. This stain is pH-sensitive and  
496 fluoresces only in acid environments such as in the lumen of amoeba food vacuole<sup>15</sup>. It is  
497 worthwhile to point out that the stain only gives information related to the internalization of  
498 cells. Determination if cells are eventually phagocytized in additional experiments may be  
499 required.

500  
501 Importantly, such a stain also proved to be useful in the measurement of fluorescence. The  
502 latter allowed integration of quantitative data in an attempt to explain what happens  
503 biologically at one specific timepoint. Here, fate of cells was discerned (i.e., it was determined  
504 whether the presence of 3-hydroxy fatty acids impaired or promoted the internalization of  
505 cells) by extrapolating meaning from the readings of relative fluorescence units.

506  
507 Unlike in this study, researchers may also opt to measure the fluorescence of cells over a time  
508 period. The obtained information is useful in determining the number of cells that are  
509 internalized at one timepoint and following how the amount changes over the period. Likewise,  
510 images can also be taken at corresponding timepoints.

511  
512 This study shows the power of combining a number of methods to reach a reasoned conclusion.  
513 The approach of combining multiple approaches to monitor phagocytosis either to compare or  
514 complement an initial technique is not new. For example, Meindl and co-workers<sup>33</sup> compared  
515 three techniques (image analysis, fluorescence, and flow cytometry readings) to investigate  
516 how fluorescence-labelled particle size affects macrophage phagocytosis. The study proved that  
517 of the three techniques, plate reading may be the best option to monitor phagocytosis<sup>33</sup>.

518  
519 TEM is particularly a powerful tool, as it provides a bird's eye view into the lumen of the food  
520 vacuole. Often, this level of detail is frequently missed by confocal microscopy in the form of  
521 still images, including time-lapse videos. To this point of the TEM, it was interesting to visualize  
522 protuberances on the surfaces of the cryptococcal capsule. It was previously hypothesized that  
523 these cell surface structures are used as a channel to release 3-hydroxy fatty acids into the

524 surrounding environment to possibly promote cell survival<sup>9,10,15,31</sup>. The detail on the TEM  
525 micrograph further reveals that protuberances on the internalized cell are not distorted and  
526 have maintained their integrity. Thus (given the integrity of the protuberances), it is possible  
527 that they may deliver 3-hydroxy fatty acids into the food vacuole environment and alter  
528 internal conditions, leading to cell survival as reported by Madu et al.<sup>15,31</sup>. A major limitation of  
529 using the electron microscope is that sample preparation is very laborious. Moreover, to avert  
530 destroying the samples as seen in **Figure 4**, the experimenter should be well-trained to  
531 manually operate the ultramicrotome and microscope.

532  
533 In conclusion, it is envisaged that researchers will be encouraged by the prospect of studying  
534 phagocytosis simply by combining still fluorescent images with quantitative data. It is trusted  
535 that researchers can obtain enough information from this protocol and optimize it in their own  
536 studies. This may include the development of antibodies against targeted metabolites and  
537 applying this to immunofluorescence studies, including immuno-gold labelling during TEM  
538 examination.

#### 539 **ACKNOWLEDGMENTS:**

541 The work was supported by a grant from the National Research Foundation of South Africa  
542 (grant number: UID 87903) and the University of the Free State. We are also grateful to services  
543 and assistance offered by Pieter van Wyk and Hanlie Grobler during our microscopy studies.

#### 544 **DISCLOSURES:**

545 The authors declare that they have no competing financial interests.

#### 546 **REFERENCES:**

- 547 1. Barton, L. L., Northup, D. E. *Microbial Ecology*. Wiley-Blackwell. New Jersey (2011).
- 548 2. Hunter, P. Entente cordiale: multiple symbiosis illustrates the intricate interconnectivity of  
549 nature. *EMBO Reports*. **7**, 861-864 (2006).
- 550 3. Comolli, L. R. Intra- and inter-species interactions in microbial communities. *Frontiers in*  
551 *Microbiology*. e629 (2014).
- 552 4. Siddiqui, R., Khan, N. A. *Acanthamoeba* is an evolutionary ancestor of macrophages: a myth  
553 or reality? *Experimental Parasitology*. **130**, 95-97 (2012).
- 554 5. Khan, N. A. *Acanthamoeba: Biology and Pathogenesis*. Caister Academic Press. Nottingham  
555 (2014).
- 556 6. Steenbergen, J. N., Casadevall, A. The origin and maintenance of virulence for the human  
557 pathogenic fungus *Cryptococcus neoformans*. *Microbes and Infection*. **5**, 667-675 (2003).
- 558 7. Casadevall, A., Perfect, J. R. *Cryptococcus Neoformans*. ASM Press. Washington D.C. (1998).
- 559 8. Axelsson-Olsson, D., Olofsson, J., Ellstrom, P., Waldenstrom, J., Olsen, B. A simple method for  
560 long term storage of *Acanthamoeba* species. *Parasitology Research*. **104**, 935-937 (2009).
- 561 9. Sebolai, O. M. et al. 3-Hydroxy fatty acids found in capsules of *Cryptococcus neoformans*.  
562 *Canadian Journal of Microbiology*. **53**, 809-812 (2007).
- 563 10. Sebolai, O. M., Pohl, C. H., Botes, P. J., van Wyk, P. W. J., Kock, J. L. F. The influence of  
564 acetylsalicylic acid on oxylipin migration in *Cryptococcus neoformans* var. *neoformans* UOFS Y-  
565 1378. *Canadian Journal of Microbiology*. **54**, 91-96 (2008).
- 566
- 567

- 568 11. Yap, A. S., Michael, M., Parton, R. G. Seeing and believing: recent advances in imaging cell-  
569 cell interactions. *F1000 Research*. e6435.1 (2015).
- 570 12. Follain, G., Mercier, L., Osmani, N., Harlepp, S., Goetz, J.G. Seeing is believing – multiscale  
571 spatio-temporal imaging towards *in vivo* cell biology. *Journal of Cell Science*. **130**, 23-38 (2017).
- 572 13. Lewis, L. E., Bain, J. M., Okai, B., Gow, N. A. R., Erwig, L.P. Live-cell video microscopy of  
573 fungal pathogen phagocytosis. *Journal of Visualized Experiments*. e50196 (2013).
- 574 14. Duane, E. G. A practical guide to implementing a BLS-2+ biosafety program in a research  
575 laboratory. *Applied Biosafety*. **18**, 30-36 (2013).
- 576 15. Madu, U. L. et al. Cryptococcal 3-hydroxy fatty acids protect cells against amoebal  
577 phagocytosis. *Frontiers in Microbiology*. e1351 (2015).
- 578 16. Smith, D., Onions, A. H. S. *The Preservation and Maintenance of Living Fungi: IMI Technical*  
579 *Handbooks No. 2*. CAB International. Wallington (1994).
- 580 17. Schuster, F. L. Cultivation of pathogenic and opportunistic free-living amebas. *Clinical*  
581 *Microbiology Reviews*. **15**, 342-344 (2002).
- 582 18. Strober, W. Trypan blue exclusion test of cell viability. *Current Protocols in Immunology*. **21**,  
583 1-2 (2001).
- 584 19. Beisker, W., Bolbeare, F., Gray, J. W. An improved immunocytochemical procedure for high  
585 sensitivity detection of incorporated bromodeoxyuridine. *Cytometry*. **8**, 235-239 (1987).
- 586 20. Clancy, B., Cauller, L. J. Reduction of background autofluorescence in brain sections  
587 following immersion in sodium borohydride. *Journal of Neuroscience Methods*. **83**, 97-102  
588 (1998).
- 589 21. Simons, E. R. Measurement of phagocytosis and of phagosomal environment in  
590 polymorphonuclear phagocytes by flow cytometry. *Current Protocols in Cytometry*. Unit 9, 31  
591 (2010).
- 592 22. Grillo-Hill, B. K., Webb, B. A., Barber, D. L. Ratiometric Imaging of pH Probes. *Methods in Cell*  
593 *Biology*. **123**, 429-448 (2014).
- 594 23. van Wyk, P. W. J., Wingfield, M. J. Ascospores ultrastructure and development in  
595 *Ophiostoma cucullatum*. *Mycologia*. **83**, 698-707 (1991).
- 596 24. Spur, A. R. A low viscosity epoxy resin embedding medium for electron microscopy.  
597 *Ultrastructural Research*. **26**, 31-43 (1969).
- 598 25. Department of Minerals and Energy. *Radioactive Waste Management Policy and Strategy*  
599 *for the Republic of South Africa*. Department of Minerals and Energy. Pretoria (2005).
- 600 26. Reynolds, E. S. The use of lead citrate at high pH as an electron opaque stain in electron  
601 microscopy. *Cell Biology*. **17**, 208-212 (1963).
- 602 27. Monici, M. Cell and tissue autofluorescence research and diagnostic applications.  
603 *Biotechnology Annual Review*. **11**, 227-256 (2005).
- 604 28. Janeway, C. A., Travers, P., Walport, M., Shlomchik, M. *Immunobiology: The Immune System*  
605 *in Health and Disease, 5<sup>th</sup> edition*. Garland Science. New York (2001).
- 606 29. Ma, H., Croudace, J. E. Lammas, D. A., May, R. C. Expulsion of live pathogenic yeast by  
607 macrophages. *Current Biology*. **16**, 2156-2160 (2006).
- 608 30. Alvarez, M., Casadevall, A. Phagosome extrusion and host-cell survival after *Cryptococcus*  
609 *neoformans* phagocytosis by macrophages. *Current Biology*. **16**, 2161-2165 (2006).



- 610 31. Madu, U. L., Ogundeji, A. O., Pohl, C. H., Albertyn, J., Sebolai, O. M. Elucidation of the role of  
611 3-hydroxy fatty acids in *Cryptococcus*-amoeba interactions. *Frontiers in Microbiology*. e765  
612 (2017).
- 613 32. Hayes, B. K., Heit, E. Inductive reasoning 2.0. *Wiley Interdisciplinary Review: Cognitive*  
614 *Science*. e1459 (2018).
- 615 33. Meindl, C., Öhlinger, K., Ober, J., Roblegg, E., Fröhlich, E. Comparison of fluorescence-based  
616 methods to determine nanoparticle uptake by phagocytes and non-phagocytic cells *in vitro*.  
617 *Toxicology*. **378**, 25-36 (2017).









**Table 1. Ingredients for making YPD agar.**

<b>Ingredient</b>	<b>Quantity</b>
bacteriological peptone	20 g/L
yeast extract	10 g/L
glucose	20 g/L
agar	15 g/L

**Table 2. Ingredients for making YNB broth.**

<b>Ingredient</b>	<b>Quantity</b>
ammonium sulfate	5 g/L
biotin	2 µg/L
calcium pantothenate	400 µg/L
folic acid	2 µg/L
inositol	2000 µg/L
niacin	400 µg/L
p-aminobenzoic acid	200 µg/L
pyridoxine hydrochloride	400 µg/L
riboflavin	200 µg/L
thiamine hydrochloride	400 µg/L
boric acid	500 µg/L
copper sulfate	40 µg/L
potassium iodide	100 µg/L
ferric chloride	200 µg/L
manganese sulfate	400 µg/L
sodium molybdate	200 µg/L
zinc sulfate	400 µg/L
monopotassium phosphate	1 g/L
magnesium sulfate	0.5 g/L
sodium chloride	0.1 g/L
calcium chloride	0.1 g/L

**Table 3. Ingredients for making ATCC medium 712.****Part I: Basal medium.**

Ingredient	Quantity
proteose peptone	20 g/L
yeast extract	1 g/L
agar (if needed)	20 g/L

**Part II: Supplements.**

Ingredient (stock solutions)	Quantity
0.05 M CaCl <sub>2</sub>	8 mL
0.4 M MgSO <sub>4</sub> x 7H <sub>2</sub> O	10 ml
0.25 M Na <sub>2</sub> HPO <sub>4</sub> x 7H <sub>2</sub> O	10 mL
0.25 M KH <sub>2</sub> PO <sub>4</sub>	10 mL
Na Citrate x 2H <sub>2</sub> O	1 g
0.005 M Fe(NH <sub>4</sub> ) <sub>2</sub> (SO <sub>4</sub> ) <sub>2</sub> x 6H <sub>2</sub> O	10 mL



Name of Material/Equipment	Company/Manufacturer	Catalog Number	Comments/Description
1,4-Diazabicyclo-[2.2.2]-octane	Sigma-Aldrich	D27802	-
1.5-mL plastic tube	Thermo Fisher Scientific	69715	-
15-mL Centrifuge tube	Thermo Fisher Scientific	7252018	-
50-mL Centrifuge tube	Thermo Fisher Scientific	1132017	-
8-Well chamber slide	Thermo Fisher Scientific	1109650	-
Acetone	Merck	SAAR1022040LC	-
Amoeba strain	ATCC®	30234™	-
ATCC medium 712	ATCC®	712™	Amoeba medium
Black 96-well microtiter plate	Thermo Fisher Scientific	152089	-
Centrifuge	Hermle	-	-
Chloroform	Sigma-Aldrich	C2432	-
Confocal microscope	Nikon	Nikon TE 2000	-
Epoxy resin:			
[1] NSA	[1] ALS	[1] R1054	-
[2] DER 736	[2] ALS	[2] R1073	-
[3] ERL Y221 resin	[3] ALS	[3] R1047R	-
[4] S1 (2-dimethylaminoethanol)	[4] ALS	[4] R1067	-
Fluorescein isothiocyanate	Sigma-Aldrich	F4274	-
Formic Acid	Sigma-Aldrich	489441	-
Fluoroskan Ascent FL	Thermo Fisher Scientific	374-91038C	Microplate reader
Glucose	Sigma-Aldrich	G8270	-
Glutaraldehyde	ALS	R1009	-
Hemocytometer	Boeco	-	-
Lead citrate	ALS	R1209	-
Liquid Chromatography Mass Spectrometer	Thermo Fisher Scientific		-
Methanol	Sigma-Aldrich	R 34,860	-
Orbital shaker	Lasec	-	-
Osmium tetroxide	ALS	R1015	-
pHrodo Green Zymosan A BioParticles	Life Technologies	P35365	This is the pH-sensitive dye
Physiological buffer solution	Sigma-Aldrich	P4417-50TAB	-
Rotary shaker	Labcon	-	-
Sodium phosphate buffer:			
[1] di-sodium hydrogen orthophosphate dihydrate	[1] Merck	[1] 106580	-
[2] sodium di-hydrogen orthophosphate dihydrate	[2] Merck	[2] 106345	
Transmission electron microscope	Philips	Philips EM 100	-
Trypan blue	Sigma-Aldrich	T8154	-
Ultramicrotome	Leica	EM UC7	-
Uranyl acetate	ALS	R1260A	-
Vacuum dessicator	Lasec	-	-
Vial	Sigma-Aldrich	29651-U	-
YNB	Lasec	239210	-
YPD agar	Sigma-Aldrich	Y-1500	-



1 Alewife Center #200  
Cambridge, MA 02140  
tel. 617.945.9051  
www.jove.com

## ARTICLE AND VIDEO LICENSE AGREEMENT

Title of Article:

THE APPLICATION OF CONFOCAL LASER SCANNING  
MICROSCOPY AND ELECTRON MICROSCOPY IN THE STUDY  
OF CRYPTOCOCCUS-AMOEBA INTERACTIONS

Author(s):

UJU L. MADU AND OLITHILE M. SEBOLAI

Item 1: The Author elects to have the Materials be made available (as described at <http://www.jove.com/publish>) via:



Standard Access



Open Access

Item 2: Please select one of the following items:



The Author is **NOT** a United States government employee.



The Author is a United States government employee and the Materials were prepared in the course of his or her duties as a United States government employee.



The Author is a United States government employee but the Materials were NOT prepared in the course of his or her duties as a United States government employee.

### ARTICLE AND VIDEO LICENSE AGREEMENT

1. **Defined Terms.** As used in this Article and Video License Agreement, the following terms shall have the following meanings: “**Agreement**” means this Article and Video License Agreement; “**Article**” means the article specified on the last page of this Agreement, including any associated materials such as texts, figures, tables, artwork, abstracts, or summaries contained therein; “**Author**” means the author who is a signatory to this Agreement; “**Collective Work**” means a work, such as a periodical issue, anthology or encyclopedia, in which the Materials in their entirety in unmodified form, along with a number of other contributions, constituting separate and independent works in themselves, are assembled into a collective whole; “**CRC License**” means the Creative Commons Attribution-Non Commercial-No Derivs 3.0 Unported Agreement, the terms and conditions of which can be found at: <http://creativecommons.org/licenses/by-nc-nd/3.0/legalcode>; “**Derivative Work**” means a work based upon the Materials or upon the Materials and other pre-existing works, such as a translation, musical arrangement, dramatization, fictionalization, motion picture version, sound recording, art reproduction, abridgment, condensation, or any other form in which the Materials may be recast, transformed, or adapted; “**Institution**” means the institution, listed on the last page of this Agreement, by which the Author was employed at the time of the creation of the Materials; “**JoVE**” means MyJove Corporation, a Massachusetts corporation and the publisher of The Journal of Visualized Experiments; “**Materials**” means the Article and / or the Video; “**Parties**” means the Author and JoVE; “**Video**” means any video(s) made by the Author, alone or in conjunction with any other parties, or by JoVE or its affiliates or agents, individually or in collaboration with the Author or any other parties, incorporating all or any portion

of the Article, and in which the Author may or may not appear.

2. **Background.** The Author, who is the author of the Article, in order to ensure the dissemination and protection of the Article, desires to have the JoVE publish the Article and create and transmit videos based on the Article. In furtherance of such goals, the Parties desire to memorialize in this Agreement the respective rights of each Party in and to the Article and the Video.

3. **Grant of Rights in Article.** In consideration of JoVE agreeing to publish the Article, the Author hereby grants to JoVE, subject to **Sections 4 and 7** below, the exclusive, royalty-free, perpetual (for the full term of copyright in the Article, including any extensions thereto) license (a) to publish, reproduce, distribute, display and store the Article in all forms, formats and media whether now known or hereafter developed (including without limitation in print, digital and electronic form) throughout the world, (b) to translate the Article into other languages, create adaptations, summaries or extracts of the Article or other Derivative Works (including, without limitation, the Video) or Collective Works based on all or any portion of the Article and exercise all of the rights set forth in (a) above in such translations, adaptations, summaries, extracts, Derivative Works or Collective Works and (c) to license others to do any or all of the above. The foregoing rights may be exercised in all media and formats, whether now known or hereafter devised, and include the right to make such modifications as are technically necessary to exercise the rights in other media and formats. If the “Open Access” box has been checked in **Item 1** above, JoVE and the Author hereby grant to the public all such rights in the Article as provided in, but subject to all limitations and requirements set forth in, the CRC License.

## ARTICLE AND VIDEO LICENSE AGREEMENT

4. **Retention of Rights in Article.** Notwithstanding the exclusive license granted to JoVE in **Section 3** above, the Author shall, with respect to the Article, retain the non-exclusive right to use all or part of the Article for the non-commercial purpose of giving lectures, presentations or teaching classes, and to post a copy of the Article on the Institution's website or the Author's personal website, in each case provided that a link to the Article on the JoVE website is provided and notice of JoVE's copyright in the Article is included. All non-copyright intellectual property rights in and to the Article, such as patent rights, shall remain with the Author.

5. **Grant of Rights in Video – Standard Access.** This **Section 5** applies if the "Standard Access" box has been checked in **Item 1** above or if no box has been checked in **Item 1** above. In consideration of JoVE agreeing to produce, display or otherwise assist with the Video, the Author hereby acknowledges and agrees that, Subject to **Section 7** below, JoVE is and shall be the sole and exclusive owner of all rights of any nature, including, without limitation, all copyrights, in and to the Video. To the extent that, by law, the Author is deemed, now or at any time in the future, to have any rights of any nature in or to the Video, the Author hereby disclaims all such rights and transfers all such rights to JoVE.

6. **Grant of Rights in Video – Open Access.** This **Section 6** applies only if the "Open Access" box has been checked in **Item 1** above. In consideration of JoVE agreeing to produce, display or otherwise assist with the Video, the Author hereby grants to JoVE, subject to **Section 7** below, the exclusive, royalty-free, perpetual (for the full term of copyright in the Article, including any extensions thereto) license (a) to publish, reproduce, distribute, display and store the Video in all forms, formats and media whether now known or hereafter developed (including without limitation in print, digital and electronic form) throughout the world, (b) to translate the Video into other languages, create adaptations, summaries or extracts of the Video or other Derivative Works or Collective Works based on all or any portion of the Video and exercise all of the rights set forth in (a) above in such translations, adaptations, summaries, extracts, Derivative Works or Collective Works and (c) to license others to do any or all of the above. The foregoing rights may be exercised in all media and formats, whether now known or hereafter devised, and include the right to make such modifications as are technically necessary to exercise the rights in other media and formats. For any Video to which this **Section 6** is applicable, JoVE and the Author hereby grant to the public all such rights in the Video as provided in, but subject to all limitations and requirements set forth in, the CRC License.

7. **Government Employees.** If the Author is a United States government employee and the Article was prepared in the course of his or her duties as a United States government employee, as indicated in **Item 2** above, and any of the licenses or grants granted by the Author hereunder exceed the scope of the 17 U.S.C. 403, then the rights granted hereunder shall be limited to the maximum

rights permitted under such statute. In such case, all provisions contained herein that are not in conflict with such statute shall remain in full force and effect, and all provisions contained herein that do so conflict shall be deemed to be amended so as to provide to JoVE the maximum rights permissible within such statute.

8. **Protection of the Work.** The Author(s) authorize JoVE to take steps in the Author(s) name and on their behalf if JoVE believes some third party could be infringing or might infringe the copyright of either the Author's Article and/or Video.

9. **Likeness, Privacy, Personality.** The Author hereby grants JoVE the right to use the Author's name, voice, likeness, picture, photograph, image, biography and performance in any way, commercial or otherwise, in connection with the Materials and the sale, promotion and distribution thereof. The Author hereby waives any and all rights he or she may have, relating to his or her appearance in the Video or otherwise relating to the Materials, under all applicable privacy, likeness, personality or similar laws.

10. **Author Warranties.** The Author represents and warrants that the Article is original, that it has not been published, that the copyright interest is owned by the Author (or, if more than one author is listed at the beginning of this Agreement, by such authors collectively) and has not been assigned, licensed, or otherwise transferred to any other party. The Author represents and warrants that the author(s) listed at the top of this Agreement are the only authors of the Materials. If more than one author is listed at the top of this Agreement and if any such author has not entered into a separate Article and Video License Agreement with JoVE relating to the Materials, the Author represents and warrants that the Author has been authorized by each of the other such authors to execute this Agreement on his or her behalf and to bind him or her with respect to the terms of this Agreement as if each of them had been a party hereto as an Author. The Author warrants that the use, reproduction, distribution, public or private performance or display, and/or modification of all or any portion of the Materials does not and will not violate, infringe and/or misappropriate the patent, trademark, intellectual property or other rights of any third party. The Author represents and warrants that it has and will continue to comply with all government, institutional and other regulations, including, without limitation all institutional, laboratory, hospital, ethical, human and animal treatment, privacy, and all other rules, regulations, laws, procedures or guidelines, applicable to the Materials, and that all research involving human and animal subjects has been approved by the Author's relevant institutional review board.

11. **JoVE Discretion.** If the Author requests the assistance of JoVE in producing the Video in the Author's facility, the Author shall ensure that the presence of JoVE employees, agents or independent contractors is in accordance with the relevant regulations of the Author's institution. If more than one author is listed at the beginning of this Agreement, JoVE may, in its sole

## ARTICLE AND VIDEO LICENSE AGREEMENT

discretion, elect not take any action with respect to the Article until such time as it has received complete, executed Article and Video License Agreements from each such author. JoVE reserves the right, in its absolute and sole discretion and without giving any reason therefore, to accept or decline any work submitted to JoVE. JoVE and its employees, agents and independent contractors shall have full, unfettered access to the facilities of the Author or of the Author's institution as necessary to make the Video, whether actually published or not. JoVE has sole discretion as to the method of making and publishing the Materials, including, without limitation, to all decisions regarding editing, lighting, filming, timing of publication, if any, length, quality, content and the like.

12. **Indemnification.** The Author agrees to indemnify JoVE and/or its successors and assigns from and against any and all claims, costs, and expenses, including attorney's fees, arising out of any breach of any warranty or other representations contained herein. The Author further agrees to indemnify and hold harmless JoVE from and against any and all claims, costs, and expenses, including attorney's fees, resulting from the breach by the Author of any representation or warranty contained herein or from allegations or instances of violation of intellectual property rights, damage to the Author's or the Author's institution's facilities, fraud, libel, defamation, research, equipment, experiments, property damage, personal injury, violations of institutional, laboratory, hospital, ethical, human and animal treatment, privacy or other rules, regulations, laws, procedures or guidelines, liabilities and other losses or damages related in any way to the submission of work to JoVE, making of videos by JoVE, or publication in JoVE or elsewhere by JoVE. The Author shall be responsible for, and shall hold JoVE harmless from, damages caused by lack of sterilization, lack of cleanliness or by contamination due to


the making of a video by JoVE its employees, agents or independent contractors. All sterilization, cleanliness or decontamination procedures shall be solely the responsibility of the Author and shall be undertaken at the Author's expense. All indemnifications provided herein shall include JoVE's attorney's fees and costs related to said losses or damages. Such indemnification and holding harmless shall include such losses or damages incurred by, or in connection with, acts or omissions of JoVE, its employees, agents or independent contractors.

13. **Fees.** To cover the cost incurred for publication, JoVE must receive payment before production and publication the Materials. Payment is due in 21 days of invoice. Should the Materials not be published due to an editorial or production decision, these funds will be returned to the Author. Withdrawal by the Author of any submitted Materials after final peer review approval will result in a US\$1,200 fee to cover pre-production expenses incurred by JoVE. If payment is not received by the completion of filming, production and publication of the Materials will be suspended until payment is received.

14. **Transfer, Governing Law.** This Agreement may be assigned by JoVE and shall inure to the benefits of any of JoVE's successors and assignees. This Agreement shall be governed and construed by the internal laws of the Commonwealth of Massachusetts without giving effect to any conflict of law provision thereunder. This Agreement may be executed in counterparts, each of which shall be deemed an original, but all of which together shall be deemed to me one and the same agreement. A signed copy of this Agreement delivered by facsimile, e-mail or other means of electronic transmission shall be deemed to have the same legal effect as delivery of an original signed copy of this Agreement.

A signed copy of this document must be sent with all new submissions. Only one Agreement is required per submission.

### CORRESPONDING AUTHOR

Name:	OLIHILE M. SEBOLAI	
Department:	MICROBIAL, BIOCHEMICAL AND FOOD BIOTECHNOLOGY	
Institution:	UNIVERSITY OF THE FREE STATE	
Title:	DR	
Signature:		Date: FRI, 29 JUNE 2018

Please submit a **signed** and **dated** copy of this license by one of the following three methods:

1. Upload an electronic version on the JoVE submission site
2. Fax the document to +1.866.381.2236
3. Mail the document to JoVE / Attn: JoVE Editorial / 1 Alewife Center #200 / Cambridge, MA 02140



Wednesday, 24 April 2019

**Dr Jaydev Upponi, Ph.D.**

Science Editor: JoVE, Immunology and Infection

Dear Dr Upponi,

We appreciate the comments made by the editorial office and the reviewers. We have prepared our responses. They are highlighted in red and follow a question/comment posed to us.

I trust you will find our responses to be sufficient. Future correspondence should be addressed to Dr. Olihile M. Sebolai (+2751 401 2004; [sebolaiom@ufs.ac.za](mailto:sebolaiom@ufs.ac.za)).

With sincere appreciation,

A handwritten signature in black ink that reads 'Olihile M. Sebolai'.

**Dr Olihile M. Sebolai (Ph.D.)**

Corresponding author

Senior Lecturer and Fulbright Fellow



## Responses to Editorial concerning the manuscript:

---

### 1. Journal's style.

We endeavored to retain the style.

### 2. Proofreading, please employ professional copyediting services.

The manuscript has been proofread.

### 3. Title:

We have revised the title. We have also used the same title for the video.

### 4. Normal consistency

We have edited out “normal consistency”. Yes, this is quantifiable. By weighing off the ingredients, one should be able to make epoxy of normal consistency.

### 5. We hypothesized

We have changed our text accordingly.

### 6. Reference

We have now included a reference.

## Responses to Editorial concerning the video:

---

### 1. Title

The title of the video matches that of the manuscript.

### 2. Flickering

We have worked on flickering. Let us know if all is in order.

Dear Dr. Sebolai

Thank you for your email.

Under the Frontiers Terms and Conditions, authors retain the copyright to their work. Furthermore, all Frontiers articles are Open Access and distributed under the terms of the Creative Commons Attribution License (CC-BY 3,0), which permits the use, distribution and reproduction of material from published articles, provided the original authors and source are credited, and subject to any copyright notices concerning any third-party content.

You can therefore freely reuse a figure of an article published at Frontiers without having to ask for permission. More information about CC-BY can be found here:

<http://creativecommons.org/licenses/by/4.0/>

Best regards,

Gearóid

---

Ethics & Integrity Manager: [Gearóid Ó Faoleán](#), PhD

#### Frontiers

[www.frontiersin.org](http://www.frontiersin.org)

EPFL Innovation Square, Building I  
Lausanne, Switzerland  
Office T [+44 79 34 46 47 49](tel:+447934464749)

For technical issues, please visit our Frontiers Help Center [frontiers.zendesk.com](http://frontiers.zendesk.com)

---

Research Integrity Manager: [Gearóid Ó Faoleán](#), PhD

#### Frontiers

[www.frontiersin.org](http://www.frontiersin.org)

Avenue du Tribunal-Fédéral 34  
1005 Lausanne, Switzerland  
Office T +44 203 514 26 98

For technical issues, please visit our Frontiers Help Center [frontiers.zendesk.com](http://frontiers.zendesk.com)

On Wed, Feb 6, 2019 at 5:41 AM Olihile Sebolai <[SebolaiOM@ufs.ac.za](mailto:SebolaiOM@ufs.ac.za)> wrote:

Dear Sir, Dear Madam:

I hope you are doing good. I'd like to request a letter from the office wherein I am granted copyright permission to re-use a figure from my previous paper that was published with Frontiers. The article in question is: U.L. Madu, A.O. Ogundeji, B.M. Mochochoko, C.H.

Pohl, J. Albertyn, C.W. Swart et al. (2015). Cryptococcal 3-hydroxy fatty acids protect cells against amoebal phagocytosis. *Frontiers in Microbiology* 6, Article no. 1351.

I am in the process of submitting a manuscript to *Journal of Visualized Experiments* based on the techniques I used to obtain the figure from my *Frontiers* paper. I trust you will find my letter to be in order and to assist me in this regard.

With sincere appreciation,



**Olihile Sebolai**

Senior Lecturer: Microbial Biochemical and Food Biotechnology  
Senior Lektor: Mikrobiëse Biochemiese en Voedselbiotegnologie  
Faculty / Fakulteit: Natural and Agricultural Sciences / Natuur- en  
Landbouwetenskappe  
PO Box / Posbus 339, Bloemfontein 9300, Republic of South Africa /  
Republiek van Suid-Afrika

+27 (0)51 401 2004

[SebolaiOM@ufs.ac.za](mailto:SebolaiOM@ufs.ac.za)





### **The extraction and analysis of 3-hydroxy fatty acids. Modified from Madu et al.<sup>15</sup>.**

NOTE: *Cryptococcus neoformans* is regarded as biosafety level-2 (BSL-2) pathogens and thus researchers ought to take the proper precautions when working with this organism. For example, laboratory personnel should have specific training and personal protective equipment (PPE) such as lab coats, gloves and eye protection. A biological safety cabinet (level-2) should be used for procedures that can cause infection<sup>14</sup>.

NOTE: The extraction should be carried out in a fume hood. Personnel should also use PPE during the course of the extraction procedure.

1. Prepare a 24 h old culture of *C. neoformans* UOFS Y-1378 as stated in sub-section 1 of the protocol. Information on YNB broth's ingredients can be found in Table 2.

NOTE: All the steps should be repeated for *C. neoformans* LMPE 046.

2. Use a hemocytometer to determine the cell concentration of the culture after 24 h.

3. Use the equation  $C_1.V_1 = C_2.V_2$  to work out how much volume of the culture media is required to yield a final cell concentration of  $1 \times 10^7$  cells/mL in a final volume of 2 mL (of the same culture medium).

4. Transfer 2 mL of the culture media, containing the cells, to a 15 mL centrifuge tube.

5. Add 3% formic acid drop-wise to decrease the pH of the culture media to 4.

NOTE: To make 3% solution, add 3 mL of formic acid to 97 mL of distilled water.

6. Add a 2 mL solution of methanol-chloroform (1:1, v/v) to the culture media in the tube.

NOTE: Prepare the above cocktail solution by adding 5 mL of methanol to 2.5 mL of chloroform.

NOTE: Do not inhale the chloroform as it may cause breathing difficulty.

7. Vortex-mix the contents of the tube for 2 min.

8. Allow the tube to stand for 20 min.

9. Add 2 mL of distilled water to the mixture in the tube.

10. Vortex-mix the contents for 5 min.

11. Centrifuge at  $1900 \times g$  for 10 min at 4 °C.

12. Collect the chloroform fraction, which contains the 3-hydroxy fatty acids.

13. Transfer this fraction to a vial.
14. Dry the contents of the vial under a stream of nitrogen in a fume hood.
15. Reconstitute the extracts in 1 mL of methanol and transfer to a 1.5-mL plastic tube.
16. Collect 200  $\mu$ L of the reconstituted extracts and transfer to an analytical vial.
17. Store the sample in the autosampler of the high-performance liquid chromatography mass spectrometer at 5 °C before injection.
18. Analyze the samples within 24 h of reconstitution in negative electronspray ionization mode.
19. Run a blank control sample at the start and end of each run.

NOTE: This will provide a measure of the sample background and also a measure of compound carry over.

20. Run a full scan mode of between  $m/z$  100–1000.

21. Obtain the relative peak area of the analyte of interest based on the retention time of the analytical standard.

NOTE: In the current study the analyte of interest was 3-hydroxy nonanoic acid i.e. 3-hydroxy C9:0.

22. Obtain the characteristic mass fragments from the mass spectrum to confirm the identity of the analyte of interest.

NOTE: These mass fragments should be similar to that of the analytical standard.